Idera Pharmaceuticals is a biopharmaceutical company focused on the clinical development, and the commercialization, of drug candidates for rare disease indications characterized by patient populations with unmet medical needs. Co.'s focus is to identify and acquire rights to development and commercial stage rare disease programs through new business development opportunities, including additional alternatives. Co. is evaluating intratumoral tilsotolimod in combination with nivolumab, an anti-Progressive Disease 1 antibody marketed as Opdivo® by Bristol Myers Squibb Company, and ipilimumab for the treatment of multiple solid tumors in a multicohort trial. The IDRA stock yearly return is shown above.
The yearly return on the IDRA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IDRA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|